No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay
Academic Article
Publication Date:
2018
abstract:
Sensitive and specific biomarkers of Pancreatic Ductal Adenocarcinoma (PDAC) are desperately needed to allow early diagnosis and improve patient's survival. Ezrin autoantibodies were recently described as present in 93% of PDAC patients and 40% of healthy subjects who later developed PDAC. However, another prospective study failed to replicate these findings. Both studies were based on the use of a solid phase ELISA immunoassay.
Iris type:
1.1 Articolo in rivista
Keywords:
LIPS; PDAC; TAA; autoantibody; biomarker
List of contributors:
Liberati, Daniela; Marzinotto, Ilaria; Brigatti, Cristina; Dugnani, Erica; Pasquale, Valentina; Reni, Michele; Balzano, Gianpaolo; Falconi, Massimo; Piemonti, Lorenzo; Lampasona, Vito
Published in: